[CAS NO. 287194-40-5] (-)-DHMEQ
PRODUCTS SPECIFICATIONS [287194-40-5]
DESCRIPTION [287194-40-5]
Overview
| MDL | MFCD11100254 |
|---|---|
| Molecular Weight | 261.23 |
| Molecular Formula | C13H11NO5 |
| SMILES | O=C1[C@@H](O2)[C@@H]2[C@@H](O)C(NC(C3=C(O)C=CC=C3)=O)=C1 |
20 Publications Citing Use of MCE
- [1]Biosens Bioelectron. 2020 Dec 30;176:112942.
- [2]Redox Biol. 2021 Sep 30;47:102157.
- [3]Theranostics. 2019 Jan 1;9(2):436-448.
- [4]Sens Actuators B Chem. 2018 Nov 20;274:481-490.
- [5]Anal Chem. 2017 Jul 18;89(14):7316-7323.
- [6]Anal Chim Acta. 2019 Feb 7;1048:168-177.
- [7]Br J Cancer. 2021 Sep 25.
- [8]Mol Cancer Ther. 2018 Jun;17(6):1303-1314.
- [9]Biomedicines. 2022, 10(1), 165.
- [10]Biomed Pharmacother. 2022 Jul 11;153:113363.
- [11]J Transl Med. 2020 Dec 3;18(1):460.
- [12]J Neuroimmune Pharmacol. 2019 Mar;14(1):94-109.
- [13]Toxicology. 2018 May 14;404-405:49-58.
- [14]Mol Cells. 2018 Dec 31;41(12):1008-1015.
- [15]Neurosci Lett. 2023: 137064.
- [16]Bioengineered. 2022 Feb;13(2):3395-3409.
- [17]Biol Pharm Bull. 2017;40(10):1669-1677.
- [18]BMC Vet Res. 2019 Oct 25;15(1):365.
- [19]bioRxiv. 2023.
- [20]bioRxiv. 2020 Apr.
Summary
IC50 & Target
|
RelA |
RelB |
In Vitro
(-)-DHMEQ (Dehydroxymethylepoxyquinomicin; 2-10 μg/mL; 12-48 hours) treatment significantly reduces the viability of all cell lines in a dose- and time-dependent manner, whereas the effect is not significant in a control cell line K562 without constitutive NF-κB activity
[2]
.
(-)-DHMEQ (10 μg/mL; 0-48 hours; TL-Om1, MT-1 and K562 cells) treatment significantly increases the Annexin V-positive cells in MT-1 and TL-Om1 cell lines
[2]
.
(-)-DHMEQ (10 μg/mL; 4-16 hours; MT-1 cells) treatment down-regulates Bcl-xL, Bcl-2, c-myc, cyclin D1, Rb, and p53, and up-regulates proapoptotic genes such as caspase-3, -8, and-9
[2]
.
(-)-DHMEQ treatment increases cells in G0 /G1 phase in a time-dependent manner, demonstrating antiproliferative effects of (-)-DHMEQ
[2]
.
(-)-DHMEQ binds to p65, cRel, RelB, and p50, but not to p52 at specific cysteine residues. (-)-DHMEQ inhibits not only DNA-binding of RelB, but also its interaction to importin. (-)-DHMEQ also induces instability of RelB
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | TL-Om1, MT-1, KK-1, ST-1 and K562 cells |
| Concentration: | 2 μg/mL, 5 μg/mL, 10 μg/mL |
| Incubation Time: | 12 hours, 24 hours, 48 hours |
| Result: | Significantly reduced the viability of all cell lines in a dose- and time-dependent manner. |
Apoptosis Analysis [2]
| Cell Line: | TL-Om1, MT-1 and K562 cells |
| Concentration: | 10 μg/mL |
| Incubation Time: | 0 hours, 24 hours, 48 hours |
| Result: | Annexin V-positive cells were significantly increased after 24 to 48 hours. |
Western Blot Analysis [2]
| Cell Line: | MT-1 cells |
| Concentration: | 10 μg/mL |
| Incubation Time: | 4 hours, 8 hours, 16 hours |
| Result: | Annexin V-positive cells were significantly increased after 24 to 48 hours. |
In Vivo
(-)-DHMEQ (Dehydroxymethylepoxyquinomicin; 4 mg/kg or 12 mg/kg; intraperitoneal injection; on day 0 and 3 times a week; for one month; SCID mice) treatment shows a significant increase in the survival rate in mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male C.B17-scid/scid (5 weeks old) mice injected with MT-2 cells [2] |
| Dosage: | 4 mg/kg or 12 mg/kg |
| Administration: | Intraperitoneal injection; on day 0 and 3 times a week; for one month |
| Result: | Showed a significant increase in the survival rate in mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 50 mg/mL ( 191.40 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.8280 mL | 19.1402 mL | 38.2804 mL |
| 5 mM | 0.7656 mL | 3.8280 mL | 7.6561 mL |
| 10 mM | 0.3828 mL | 1.9140 mL | 3.8280 mL |
-
1.
References
- [1] Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.
- [2] Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106(7):2462-
- [3] Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677.
